Thymosin Alpha-1
Immune modulator. Thymosin Alpha-1 is not FDA approved for any use.
Key facts
- Class
- Immune modulator
- Also called
- TA1, thymalfasin
- Half-life
- elimination half-life less than 3 hours; Tmax 1-2 hours
- subcutaneous, in people · International journal of clinical pharmacology and therapeutics 1999, PMID 10027483
- FDA status
- Not approved
- approved abroad
- WADA
- Unclear
- Not named on the 2026 list
Thymosin Alpha-1 guides
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Immune system | 222 | 101 | 10 | Human RCT evidence, 4 of 4BMJ 2025, PMID 39814420 |
| Liver | Not in our ledger | Not in our ledger | 4 | Human RCT evidence, 4 of 4Internal medicine 2003, PMID 14606705 |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
The strongest finding is a result showing no benefit
The largest trial, in septic patients, found 28-day mortality of 23.4% on thymosin alpha 1 against 24.1% on placebo, with a hazard ratio of 0.99.[4]
A meta-analysis of sepsis trials found lower mortality overall, but the high-quality and multicentre subgroups did not show a mortality benefit.[7]
An earlier review of small sepsis trials reported a significant mortality decrease.[8]
Other conditions: disagreement or low-certainty evidence
For COVID-19, a large meta-analysis found no statistically significant effect on mortality.[9]
A different COVID-19 meta-analysis found significantly lower mortality, so the meta-analyses disagree.[10]
For chronic hepatitis B, a Cochrane review judged that thymosin alpha 1 may reduce all-cause mortality, but on very low-certainty evidence.[11]
In healthy volunteers, the elimination half-life was short, less than 3 hours.[5]
Regulatory path
Drugs@FDA has no thymosin alpha-1 (thymalfasin) product.[2]
FDA's safety-risk table flags an immunogenicity risk for compounded thymosin-alpha-1 by certain routes.[3]
WADA's S2.3 names thymosin-beta-4 and its derivatives. Thymosin alpha-1 is a different peptide and is not in the quoted line.[1]
Common questions
Is Thymosin Alpha-1 FDA approved?
No. Thymosin Alpha-1 is not FDA approved for any use.
What does thymosin alpha 1 do?
In the largest sepsis trial it did not lower 28-day mortality compared with placebo.[4]
Is there thymosin alpha 1 nasal spray or oral?
The pharmacokinetic study tested subcutaneous formulations only; no nasal or oral study was found.[5]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "Thymosin Alpha-1" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3US compounding: Thymosin alpha-1 appears in FDA's table of bulk drug substances previously in category 2 and withdrawn by the nominators.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 4The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025PMID 39814420Accessed 2 Oct 2026
- 5Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers.International journal of clinical pharmacology and therapeutics · 1999PMID 10027483Accessed 2 Oct 2026
- 6A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.Internal medicine (Tokyo, Japan) · 2003PMID 14606705Accessed 2 Oct 2026
- 7Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in cellular and infection microbiology · 2025PMID 40969554Accessed 2 Oct 2026
- 8The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.BMC infectious diseases · 2016PMID 27633969Accessed 2 Oct 2026
- 9Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.International immunopharmacology · 2023PMID 36527881Accessed 2 Oct 2026
- 10The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.Inflammopharmacology · 2023PMID 37845598Accessed 2 Oct 2026
- 11Thymosin-ɑ1 for people with chronic hepatitis B.The Cochrane database of systematic reviews · 2026PMID 42713852Accessed 2 Oct 2026
Found an error? Report a correction.